Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that within California, where the average treatment rate of psoriasis is 45 percent, the rates of treatment can fluctuate between 30 percent and 61 percent depending on the individual metropolitan statistical area.
"By using our PatientFinder model of local epidemiology we found that local prescription volumes in San Francisco and San Jose suggest that these metropolitan statistical areas have the highest treatment rates in the state, while Riverside and Bakersfield both have some of the lowest treatment rates," states Jason LaBonte, Ph.D, vice president of new product development at Decision Resources.
The new analytics tools from Decision Resources entitled PatientFinder: Psoriasis also reveals that while the city of Los Angeles has a near-average treatment rate of 48 percent, its high prevalence of disease means that there are still over 60,000 non-drug treated patients available in this metropolitan statistical area.
Why Pharmaceutical Companies Need this Information
With the type of information included in PatientFinder, pharmaceutical organizations can identify the local markets that offer the greatest opportunity for their branded drug. Companies can identify markets that are underserved and determine if they should increase direct-to-consumer advertising, work with the local managed care organizations to increase awareness of the disease and benefits of their drug or align sales representatives to maximize market potential.
PatientFinder is the only healthcare analytics tool that assesses local markets for expansion opportunity by determining the number of insured patients in each territory who have the disease but are untreated. PatientFinder covers each of the 50 U.S. states and 318 U.S. metropolitan statistical areas (MSAs) and provides:
-- Disease-specific prevalence numbers for each U.S. state and MSA -- Examination of treatment rates for the disease population to create percent treated and percent untreated estimates by state and MSA -- Unique analysis of the untreated population examined through a filter of prescription (Rx) benefit coverage. The end result is an estimate of how many patients are untreated but can afford therapy within each territory -- the true local measure of opportunity for pharmaceutical companies About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 email@example.com firstname.lastname@example.org
SOURCE: Decision Resources
Contact: Natalia Morales, +1-781-296-2691, email@example.com, or
Elizabeth Marshall, +1-781-296-2563, firstname.lastname@example.org, both of
Decision Resources, Inc.
Web site: http://www.decisionresources.com/